BRPI0106682B8 - molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto - Google Patents

molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto

Info

Publication number
BRPI0106682B8
BRPI0106682B8 BRPI0106682A BRPI0106682A BRPI0106682B8 BR PI0106682 B8 BRPI0106682 B8 BR PI0106682B8 BR PI0106682 A BRPI0106682 A BR PI0106682A BR PI0106682 A BRPI0106682 A BR PI0106682A BR PI0106682 B8 BRPI0106682 B8 BR PI0106682B8
Authority
BR
Brazil
Prior art keywords
antibody molecule
compound
antibody
cloning
therapeutic
Prior art date
Application number
BRPI0106682A
Other languages
English (en)
Portuguese (pt)
Inventor
George Popplewell Andrew
Neil Charles Weir Andrew
Paul Chapman Andrew
John King David
Thomas Brown Derek
Singh Athwal Diljeet
Original Assignee
Celltech R&D Ltd
Ucb Pharma Sa
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0106682(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd, Ucb Pharma Sa, Ucb Sa filed Critical Celltech R&D Ltd
Publication of BRPI0106682B1 publication Critical patent/BRPI0106682B1/pt
Publication of BRPI0106682B8 publication Critical patent/BRPI0106682B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
BRPI0106682A 2000-06-06 2001-06-05 molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto BRPI0106682B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0013810.7 2000-06-06
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
BRPI0106682B1 BRPI0106682B1 (pt) 2020-10-13
BRPI0106682B8 true BRPI0106682B8 (pt) 2021-05-25

Family

ID=9893121

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0106682A BRPI0106682B8 (pt) 2000-06-06 2001-06-05 molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto
BR0106682-0A BR0106682A (pt) 2000-06-06 2001-06-05 Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0106682-0A BR0106682A (pt) 2000-06-06 2001-06-05 Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo

Country Status (42)

Country Link
US (4) US7012135B2 (enEXAMPLES)
EP (4) EP3059314B1 (enEXAMPLES)
JP (3) JP4064812B2 (enEXAMPLES)
KR (1) KR20020047097A (enEXAMPLES)
CN (1) CN1289671C (enEXAMPLES)
AP (1) AP2092A (enEXAMPLES)
AR (1) AR033978A1 (enEXAMPLES)
AT (1) ATE451460T1 (enEXAMPLES)
AU (1) AU783756B2 (enEXAMPLES)
BE (1) BE2010C019I2 (enEXAMPLES)
BG (1) BG66072B1 (enEXAMPLES)
BR (2) BRPI0106682B8 (enEXAMPLES)
CA (2) CA2707766C (enEXAMPLES)
CY (6) CY1109889T1 (enEXAMPLES)
CZ (1) CZ300737B6 (enEXAMPLES)
DE (3) DE10192353T1 (enEXAMPLES)
DK (4) DK2308975T3 (enEXAMPLES)
EC (1) ECSP024210A (enEXAMPLES)
ES (5) ES2403217T3 (enEXAMPLES)
FR (1) FR10C0015I2 (enEXAMPLES)
GB (2) GB0013810D0 (enEXAMPLES)
HU (4) HU230669B1 (enEXAMPLES)
IL (3) IL147992A0 (enEXAMPLES)
IS (2) IS2808B (enEXAMPLES)
LT (1) LT2308975T (enEXAMPLES)
LU (1) LU91674I2 (enEXAMPLES)
MX (1) MXPA01013440A (enEXAMPLES)
MY (1) MY136603A (enEXAMPLES)
NL (1) NL300982I9 (enEXAMPLES)
NO (4) NO334808B1 (enEXAMPLES)
NZ (1) NZ516596A (enEXAMPLES)
OA (1) OA12282A (enEXAMPLES)
PE (1) PE20020292A1 (enEXAMPLES)
PL (2) PL218516B1 (enEXAMPLES)
PT (4) PT1287140E (enEXAMPLES)
RU (1) RU2303604C2 (enEXAMPLES)
SI (3) SI1287140T1 (enEXAMPLES)
SK (1) SK288343B6 (enEXAMPLES)
TR (1) TR201900227T4 (enEXAMPLES)
TW (2) TWI353358B (enEXAMPLES)
WO (1) WO2001094585A1 (enEXAMPLES)
ZA (1) ZA200200097B (enEXAMPLES)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US20060171940A1 (en) * 2002-03-20 2006-08-03 Celltech R&D Limited Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PL224150B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
PT1944322E (pt) * 2002-07-19 2015-07-01 Abbvie Biotechnology Ltd Tratamento de distúrbios relacionados com tnf-alfa
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003277828B2 (en) 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
BRPI0407511A (pt) * 2003-02-19 2006-02-14 Pharmacia Corp ésteres de polietilenoglicol ativados
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
ES2391457T3 (es) * 2003-08-13 2012-11-26 Sandoz Ag Procedimiento para la purificación de polipéptidos recombinantes
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
AU2006254333B2 (en) * 2005-06-01 2011-02-17 Amgen Research (Munich) Gmbh Anti-IL2 antibodies
RU2415151C2 (ru) 2005-06-07 2011-03-27 Эсбатек Аг СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
RU2503463C2 (ru) 2006-07-03 2014-01-10 Чарльз Дэвид ЭДЕЙР Композиция для модулирования экспрессии молекул клеточной адгезии
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101652128B (zh) * 2007-03-02 2012-12-19 法纳姆公司 使用蜡状材料的缓释组合物
US20080305115A1 (en) * 2007-06-07 2008-12-11 Tice Thomas R Reduced-mass, long-acting dosage forms
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2185188B1 (en) * 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2009097704A1 (en) * 2008-02-05 2009-08-13 Esbatech Ag Antigen-binding polypeptides against cartilage degeneration
EP2279207B1 (en) * 2008-05-07 2015-09-09 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
HRP20170615T1 (hr) 2008-06-25 2017-07-28 Esbatech, An Alcon Biomedical Research Unit Llc Stabilna i topiva protutijela koja inhibiraju vegf
EP3628686B1 (en) 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
ES2890405T3 (es) 2008-06-25 2022-01-19 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
EP2307457B2 (en) 2008-06-25 2022-06-22 Novartis AG Stable and soluble antibodies inhibiting tnf
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8383778B2 (en) * 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
BR112012006670B8 (pt) 2009-09-24 2022-03-03 Ucb Pharma Sa Célula bacteriana gram-negativa recombinante, e, método para produzir uma proteína recombinante
EA201792376A3 (ru) 2009-10-23 2018-08-31 Милленниум Фармасьютикалз, Инк. Молекулы анти-gcc антитела и соответствующие композиции и способы
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
SG184473A1 (en) 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP6175428B2 (ja) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 細菌のポリシストロン性発現系
KR102023786B1 (ko) 2011-07-13 2019-09-20 유씨비 파마, 에스.에이. 재조합 dsbc를 발현하는 세균 숙주 균주
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
WO2013041672A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
EP2882776B1 (en) 2012-08-13 2018-05-02 F.Hoffmann-La Roche Ag Anti-jagged anitbodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
MX381459B (es) 2014-12-22 2025-03-12 Ucb Biopharma Sprl Metodo de manufactura de proteina.
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3402499B1 (en) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
HRP20210924T1 (hr) * 2016-06-02 2021-09-03 Abbvie Inc. Agonist glukokortikoidnog receptora i njegovi imunokonjugati
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
SI3658192T1 (sl) 2017-12-01 2021-08-31 Abbvie Inc. Agonist glukokortikoidnega receptorja in njegovi imunokonjugati
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240226295A9 (en) 2021-02-15 2024-07-11 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
KR20240099199A (ko) 2021-09-24 2024-06-28 엑스브레인 바이오파마 에이비 재조합 단백질을 발현시키기 위한 dna 구조체 및 숙주 세포
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
EP0916678A3 (en) * 1993-06-03 1999-05-26 Therapeutic Antibodies Inc. Method of clotting blood
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0871641A4 (en) 1995-04-20 2001-09-26 Kennedy Inst Of Rheumatology MULTIPLE ADMINISTRATION OF ANTI-TNF ANTIBODIES
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
DK1287140T3 (da) 2010-04-19
CA2380298C (en) 2010-09-28
IS3016B (is) 2019-10-15
BG106278A (bg) 2002-12-29
NO2014026I1 (no) 2014-10-23
US20060233800A1 (en) 2006-10-19
TR201900227T4 (tr) 2019-02-21
HU230669B1 (hu) 2017-07-28
SK288343B6 (sk) 2016-04-01
NO2014026I2 (no) 2018-02-14
NO20160694A1 (no) 2002-04-08
AP2002002690A0 (en) 2002-12-31
BRPI0106682B1 (pt) 2020-10-13
HUP1600016A2 (en) 2002-10-28
JP2009171966A (ja) 2009-08-06
HK1148776A1 (en) 2011-09-16
CY1109889T1 (el) 2012-01-25
CZ300737B6 (cs) 2009-07-29
ATE451460T1 (de) 2009-12-15
DE122010000027I1 (de) 2010-08-12
PL218516B1 (pl) 2014-12-31
HUP0202346A3 (en) 2004-11-29
EP1287140B1 (en) 2009-12-09
IL147992A (en) 2009-06-15
IS2808B (is) 2012-09-15
NO20131316L (no) 2002-04-08
HUP0202346A2 (en) 2002-10-28
SI1287140T1 (sl) 2010-04-30
ES2230975A1 (es) 2005-05-01
KR20020047097A (ko) 2002-06-21
ECSP024210A (es) 2002-05-23
ZA200200097B (en) 2003-01-06
CY2019018I2 (el) 2020-05-29
NO339282B1 (no) 2016-11-21
FR10C0015I2 (fr) 2011-12-30
CZ2002837A3 (cs) 2002-05-15
EP3059314B1 (en) 2018-10-24
CN1289671C (zh) 2006-12-13
JP5185143B2 (ja) 2013-04-17
TWI316088B (en) 2009-10-21
NO20020554L (no) 2002-04-08
PT1287140E (pt) 2010-03-08
GB2366800B (en) 2005-01-19
GB2366800A (en) 2002-03-20
GB0013810D0 (en) 2000-07-26
WO2001094585A1 (en) 2001-12-13
CY2010011I1 (el) 2012-01-25
JP2003535591A (ja) 2003-12-02
NL300982I1 (enEXAMPLES) 2019-05-01
AP2092A (en) 2010-02-28
EP3059314A1 (en) 2016-08-24
JP2007105043A (ja) 2007-04-26
NZ516596A (en) 2004-07-30
LT2308975T (lt) 2016-11-10
HK1051385A1 (en) 2003-08-01
DK2308975T3 (da) 2016-10-31
CY1118220T1 (el) 2017-06-28
HU230561B1 (hu) 2016-12-28
ES2403217T3 (es) 2013-05-16
TW200817430A (en) 2008-04-16
BR0106682A (pt) 2002-05-14
DK3059314T3 (en) 2019-02-18
IL195085A0 (en) 2009-08-03
ES2707714T3 (es) 2019-04-04
BG66072B1 (bg) 2011-01-31
NO20020554D0 (no) 2002-02-04
OA12282A (en) 2006-05-11
LU91674I2 (fr) 2010-05-31
US7012135B2 (en) 2006-03-14
JP4064812B2 (ja) 2008-03-19
IS6217A (is) 2002-01-03
MY136603A (en) 2008-10-31
EP2230308B1 (en) 2013-01-23
ES2600080T3 (es) 2017-02-07
JP4476989B2 (ja) 2010-06-09
PT3059314T (pt) 2019-02-01
EP2230308A1 (en) 2010-09-22
LU91674I9 (enEXAMPLES) 2019-01-03
CN1383450A (zh) 2002-12-04
CY1114143T1 (el) 2016-07-27
US7402662B2 (en) 2008-07-22
CA2707766A1 (en) 2001-12-13
NO341218B1 (no) 2017-09-11
DK2230308T3 (da) 2013-05-06
EP2308975B1 (en) 2016-08-10
SI2230308T1 (sl) 2013-06-28
AU6051101A (en) 2001-12-17
US20030026805A1 (en) 2003-02-06
HUP1600483A2 (enEXAMPLES) 2002-10-28
GB0128386D0 (en) 2002-01-16
DE60140738D1 (de) 2010-01-21
AU783756B2 (en) 2005-12-01
CA2707766C (en) 2013-05-21
SK3152002A3 (en) 2002-07-02
ES2230975B2 (es) 2007-04-16
US20080269465A1 (en) 2008-10-30
CY1121173T1 (el) 2020-05-29
NO334808B1 (no) 2014-06-02
CY2010011I2 (el) 2012-01-25
FR10C0015I1 (enEXAMPLES) 2010-04-16
EP2308975A1 (en) 2011-04-13
TWI353358B (en) 2011-12-01
CA2380298A1 (en) 2001-12-13
NL300982I9 (nl) 2019-05-06
PL212738B1 (pl) 2012-11-30
IL147992A0 (en) 2002-09-12
PL353960A1 (en) 2003-12-15
AR033978A1 (es) 2004-01-21
CY2019018I1 (el) 2020-05-29
RU2303604C2 (ru) 2007-07-27
US7186820B2 (en) 2007-03-06
BE2010C019I2 (enEXAMPLES) 2020-08-20
DE10192353T1 (de) 2003-05-22
HUS1700013I1 (hu) 2017-08-28
US7977464B2 (en) 2011-07-12
PE20020292A1 (es) 2002-05-08
SI2308975T1 (sl) 2016-11-30
MXPA01013440A (es) 2003-09-04
US20020151682A1 (en) 2002-10-17
HU230553B1 (hu) 2016-11-28
PL399351A1 (pl) 2012-12-17
EP1287140A1 (en) 2003-03-05
ES2337763T3 (es) 2010-04-29
PT2308975T (pt) 2016-11-14
PT2230308E (pt) 2013-05-03

Similar Documents

Publication Publication Date Title
BRPI0106682B8 (pt) molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto
BR0212756A (pt) Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
O'Donnell et al. Total reconstitution of DNA polymerase III holoenzyme reveals dual accessory protein clamps.
NO336201B1 (no) Antistoffmolekyl spesifikt for humant CD22, dets terapeutiske anvendelse og fremgangsmåte for dets fremstilling
BR0307837A (pt) Anticorpos anti-abeta e seu uso
WO2004076489A8 (en) Modified antibody
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
BRPI0619595B8 (pt) anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
CA2281952A1 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
WO1998006841A3 (en) Two human nsp-like proteins
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
BR9904475A (pt) Molécula tipo anticorpo anti-fas, humanizada, agente para a profilaxia e/ou tratamento de condições envolvendo uma anormalidade no sistema ligando fas/fas, uso de um anticorpo, dna, vetor de dna recombinante, célula hospedeira, processo para produzir um anticorpo anti-pas, cepa transformante de e.coli, e, polipeptìdeo.
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
ATE393170T1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
BRPI0309730B8 (pt) molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica
TH87139B (th) การรักษาโรคโดยใช้ระบบการแสดงออกที่ควบคุมซึ่งปรับปรุงให้ดีขึ้น

Legal Events

Date Code Title Description
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 05/06/2021